Bomedemstat - Imago BioSciences
Alternative Names: Bomedemstat tosylate - Imago BioSciences; IMG-241 bis-tosylate salt; IMG-7289; LSD1 inhibitor - Imago BioSciences; MK-3543Latest Information Update: 18 Jun 2024
At a glance
- Originator Imago BioSciences
- Developer Imago BioSciences; University of Hong Kong
- Class Amides; Amines; Antihaemorrhagics; Antineoplastics; Benzamides; Benzene derivatives; Cyclopropanes; Fluorobenzenes; Piperazines; Small molecules; Triazoles
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Essential thrombocythaemia; Polycythaemia vera
- Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Myelofibrosis
- Phase I/II Small cell lung cancer
Most Recent Events
- 13 Jun 2024 Merck Sharp & Dohme plans the phase III MK-3543-007 trial for Essential thrombocythaemia (First-line therapy) (PO) (NCT06456346)
- 23 May 2024 Phase-III clinical trials in Polycythaemia vera in Australia (PO) (NCT06351631)
- 23 May 2024 Phase-III clinical trials in Polycythaemia vera in New Zealand (PO) (NCT06351631)